RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+8.19%0
Insider buys (3m)
4
Insider sells (3m)
-$435.0K
Net value (3m)
+15.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Taylor Ben R · officer: Chief Financial Officer | F-InKind | 5,396 | $3.41 |
| Sep 10, 2026 | Khan Najat · director, officer: CEO and President | Sale | 22,408 | $3.52 |
| Sep 2, 2026 | Borgeson Blake · director | Sale | 30,000 | $3.34 |
| Aug 18, 2026 | Taylor Ben R · officer: Chief Financial Officer | F-InKind | 25,018 | $3.16 |
| Aug 18, 2026 | Hallett David · officer: Chief Scientific Officer | F-InKind | 26,657 | $3.16 |
| Aug 18, 2026 | Khan Najat · director, officer: CEO and President | F-InKind | 80,498 | $3.16 |
| Aug 6, 2026 | Borgeson Blake · director | Sale | 30,000 | $3.25 |
| Jul 9, 2026 | Borgeson Blake · director | Sale | 40,000 | $3.96 |
| Jul 2, 2026 | Dar Zavain · director | A-Award | 5,109 | $0.00 |
| Jul 2, 2026 | Li Dean Y · director | A-Award | 3,747 | $0.00 |
| Jun 22, 2026 | HERSHBERG ROBERT · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Michor Franziska · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Li Dean Y · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Borgeson Blake · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Bumpus Namandje · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Dar Zavain · director | A-Award | 88,424 | $0.00 |
| Jun 22, 2026 | Bumpus Namandje · director | Sale | 3,963 | $3.18 |
| Jun 22, 2026 | Sun Elaine D · director | A-Award | 88,424 | $0.00 |
| Jun 17, 2026 | Taylor Ben R · officer: Chief Financial Officer | F-InKind | 5,396 | $3.15 |
| Jun 5, 2026 | Khan Najat · director, officer: CEO and President | Sale | 23,588 | $3.58 |
| Jun 5, 2026 | Gibson Christopher · director | Sale | 40,000 | $3.62 |
| Jun 4, 2026 | Borgeson Blake · director | Sale | 30,000 | $3.68 |
| Jun 4, 2026 | Bumpus Namandje · director | Sale | 4,386 | $3.54 |
| May 27, 2026 | Gibson Christopher · director | Sale | 40,000 | $3.08 |
| May 19, 2026 | Hallett David · officer: Chief Scientific Officer | F-InKind | 26,657 | $3.04 |
| May 19, 2026 | Khan Najat · director, officer: CEO and President | F-InKind | 62,701 | $3.04 |
| May 19, 2026 | Taylor Ben R · officer: Chief Financial Officer | F-InKind | 25,018 | $3.04 |
| May 19, 2026 | Gibson Christopher · director | F-InKind | 22,821 | $3.04 |
| May 8, 2026 | Gibson Christopher · director | Sale | 40,000 | $3.37 |
| May 7, 2026 | Borgeson Blake · director | Sale | 30,000 | $3.52 |
Institutional positioning
13F filings over the trailing two quarters
New 115Increased 265Reduced 189Sold out 44
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 50,304,691 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 43,192,306 | May 13, 2026 |
| ARK Investment Management LLC | Increased | 41,337,632 | Aug 14, 2026 |
| ARK INVESTMENT MANAGEMENT LLC | Increased | 40,212,769 | May 12, 2026 |
| STATE STREET CORP | Increased | 34,706,130 | Aug 7, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 31,131,599 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 28,490,638 | May 15, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 23,675,407 | May 8, 2026 |
| BAILLIE GIFFORD & CO | Reduced | 23,487,907 | Aug 6, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 22,765,940 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 22,759,100 | May 8, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 22,244,387 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 13,819,135 | Aug 12, 2026 |
| SOFTBANK GROUP CORP. | Unchanged | 13,636,515 | Aug 14, 2026 |
| SOFTBANK GROUP CORP. | Unchanged | 13,636,515 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 16, 2026